Somatostatin analogue associated gallstones

## **SUPPLEMENTARY MATERIAL**

Aapkes, S.E., de Haas, R.J., Bernts, L.H.P., Blijdorp, C.J., Dekker, S.E.I., van Gastel, M.D.A., Meijer, E. Veldman, A., Drenth, J.P.H., Gansevoort, R.T. Incident gallstones during somatostatin analogue treatment are associated with acute biliary complications especially after discontinuation. Drug Safety


## **Correspondence:**

Prof. R.T. Gansevoort, Department of Nephrology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. Phone: +3150 3616161, email: <a href="mailto:r.t.gansevoort@umcg.nl">r.t.gansevoort@umcg.nl</a>

## Supplementary table 1: Incidence of symptoms possibly indicative of gallstones in ADPKD patients treated with lanreotide with and without incident gallstones during treatment.

Patients treated with lanreotide	Incident gallstones during study N (%)	No incident gallstones during study (N%)	P value
Symptoms			
Abdominal cramps	11 (57.9)	50 (47.6)	0.41
Abdominal pain	9 (47.4)	39 (37.1)	0.40
Discolored stool	10 (52.6)	52 (49.5)	0.80
Hepatic cyst infection	0 (0)	6 (5.7)	0.29

## Supplementary Fig. 1. Treatment duration, discontinuation, and time until complication



Abbreviations are: EOT, end of treatment